Xenetic Biosciences (Xenetic Biosciences) 6-1 Month Momentum % : N/A% (As of Jun. 13, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Xenetic Biosciences 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-06-13), Xenetic Biosciences's 6-1 Month Momentum % is N/A%.

The industry rank for Xenetic Biosciences's 6-1 Month Momentum % or its related term are showing as below:

XBIOW's 6-1 Month Momentum % is not ranked ^*
in the Biotechnology industry.
Industry Median: -4.84
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Competitive Comparison of Xenetic Biosciences's 6-1 Month Momentum %

For the Biotechnology subindustry, Xenetic Biosciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenetic Biosciences's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's 6-1 Month Momentum % falls into.

Xenetic Biosciences (NAS:XBIOW) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences (NAS:XBIOW) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Xenetic Biosciences 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenetic Biosciences (Xenetic Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIOW) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

XBIO:USA

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.